Moderna shares soar after cancer vaccine cuts melanoma recurrence
Late-stage trial marks the first successful Phase III result for an mRNA cancer vaccine, boosting hopes for a new personalised treatment for high-risk melanoma patients
Reuters2 min read
Share

Interim results from the ongoing Phase III study showed that the treatment, known as Intismeran, met both its primary goal of reducing cancer recurrence and its secondary objective of preventing the disease from spreading to other parts of the body, compared with Keytruda alone. Picture used for illustrative purpose. REUTERS
Add Emirates 24|7 to your Google News
Text Size:
